1: Prados-Carmona A, Ruiz-Villaverde R, Ruiz-Carrascosa JC. Rupioid psoriasis.
Semergen. 2023 Oct;49(7):102061. doi: 10.1016/j.semerg.2023.102061. Epub 2023
Sep 8. PMID: 37690349.
2: Belinchón I, Velasco M, Ara-Martín M, Armesto Alonso S, Baniandrés Rodríguez
O, Ferrándiz Pulido L, García-Bustinduy M, Martínez-López JA, Martínez Sánchez
N, Pérez Ferriols A, Pérez Pascual E, Rivera Díaz R, Ruiz-Villaverde R, Taberner
Ferrer R, Vicente Villa A, Carrascosa JM. Management of Psoriasis During
Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement.
Actas Dermosifiliogr (Engl Ed). 2021 Mar;112(3):225-241. English, Spanish. doi:
10.1016/j.ad.2020.10.002. Epub 2020 Oct 13. PMID: 33065101.
3: Sahuquillo-Torralba A, Hospital-Gil M, Vilarrasa-Rull E, Llamas-Velasco M,
Rivera R, Carrascosa JM, de la Cueva-Dovao P, Armesto-Santos S, Ruíz-Villaverde
R, Velasco-Pastor M, Magdaleno-Tapial J, Yanguas-Bayona JI, Ribera-Pibernat M,
Salgado-Boquete L, Herranz-Pinto P, Romero-Mate A, Martínez-Lorenzo E, López-
Estebaranz JL, Ballescá-López F, Botella-Estrada R. Effectiveness and safety of
brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A
multicentre retrospective study in a Spanish population. Australas J Dermatol.
2023 Nov;64(4):e317-e326. doi: 10.1111/ajd.14130. Epub 2023 Jul 12. PMID:
37435962.
4: Ruiz-Villaverde R, Galán-Gutierrez M. Biosimilars in psoriasis: what should
your positioning be? Expert Opin Biol Ther. 2021 Jan;21(1):81-86. doi:
10.1080/14712598.2020.1798924. Epub 2020 Jul 27. PMID: 32684012.
5: Aguayo-Carreras P, Ruiz-Carrascosa JC, Ruiz-Villaverde R, Molina-Leyva A.
Four years stability of type D personality in patients with moderate to severe
psoriasis and its implications for psychological impairment. An Bras Dermatol.
2021 Sep-Oct;96(5):558-564. doi: 10.1016/j.abd.2021.02.005. Epub 2021 Jul 15.
PMID: 34274184; PMCID: PMC8441460.
6: Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, Ruiz-Villaverde R,
Llamas-Velasco MDM, Rocamora V, Julià M, Notario J, Fernández-Freire LR,
Sahuquillo-Torralba A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P,
Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of
psoriasis in real-world settings at 24 weeks: A retrospective, observational,
multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022
Feb;35(2):e15231. doi: 10.1111/dth.15231. Epub 2022 Jan 17. PMID: 34820971.
7: Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, C
Armario-Hita J, Pérez-Gil A, Galán-Gutiérrez M. Super-Responders in Moderate-
Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future
Perspectives. Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.
PMID: 36143449; PMCID: PMC9505180.8
8: Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R,
López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M,
Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar
E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-
Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la
Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M; Spanish Psoriasis Group
of the Spanish Academy of Dermatology and Venereology. Effectiveness and safety
of tildrakizumab for the treatment of psoriasis in real-world settings at
24 weeks: A retrospective, observational, multicentre study by the Spanish
Psoriasis Group. J Eur Acad Dermatol Venereol. 2023 Aug 25. doi:
10.1111/jdv.19468. Epub ahead of print. PMID: 37625815.
9: Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande
A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R,
Carrascosa JM; Grupo Multidisciplinar y Grupo de Consenso. Selection of Quality
Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi
Consensus Study. Actas Dermosifiliogr. 2023 Nov-Dec;114(10):865-883. English,
Spanish. doi: 10.1016/j.ad.2023.02.002. Epub 2023 Feb 15. PMID: 36796538.
10: Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande
A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R,
Carrascosa JM; Multidisciplinary Group and Consensus Group. [Translated article]
Selection of Quality Indicators for the Certification of Psoriasis Units: The
CUDERMA Project Delphi Consensus Study. Actas Dermosifiliogr. 2023 Nov-
Dec;114(10):T865-T883. English, Spanish. doi: 10.1016/j.ad.2023.09.001. Epub
2023 Sep 9. PMID: 37678630.
11: Galan-Gutierrez M, Font-Ugalde P, Padilla L, Hernandez-Montoya C, Godoy D,
Armario-Hita JC, Ruiz-Villaverde R. Brodalumab: Efficacy, safety, and survival
in mid-term (52 weeks) on real clinical practice in Andalucia, Spain. Int J
Dermatol. 2023 May;62(5):700-706. doi: 10.1111/ijd.16527. Epub 2022 Dec 10.
PMID: 36495585.
12: Navarro-Triviño FJ, Lozano-Lozano M, Ruiz-Villaverde R.
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A
Prospective, Observational, Non-Interventional, Single-Center Study of Patient
Adherence and Satisfaction in Daily Use. Dermatol Pract Concept. 2021 May
20;11(3):e2021056. doi: 10.5826/dpc.1103a56. PMID: 34123560; PMCID: PMC8172017.
13: Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de
la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML,
Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, Jaén
Olasolo P. Family Planning Concerns Among Women With Psoriasis: A Descriptive,
Cross-Sectional, Multicenter Study. Actas Dermosifiliogr. 2023 Jul
11:S0001-7310(23)00532-X. English, Spanish. doi: 10.1016/j.ad.2023.06.015. Epub
ahead of print. PMID: 37442420.
14: Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Galán-Gutiérrez M. Guselkumab: Mid-term effectiveness, drug survival, and
safety in real clinical practice. Dermatol Ther. 2021 Mar;34(2):e14798. doi:
10.1111/dth.14798. Epub 2021 Feb 7. PMID: 33484067.
15: Ruiz-Villaverde R, Rodríguez Fernández-Freire L, Galán-Gutiérrez M, Armario-
Hita JC, Martinez-Pilar L. Secukinumab: Drug Survival in Clinical Practice
Settings. Actas Dermosifiliogr (Engl Ed). 2021 Apr;112(4):361-364. English,
Spanish. doi: 10.1016/j.ad.2019.05.018. Epub 2020 Oct 28. PMID: 33129781.
16: Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de
la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML,
Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, Jaén
Olasolo P. [[Translated article]]Family Planning Concerns Among Women With
Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study. Actas
Dermosifiliogr. 2023 Nov 1:S0001-7310(23)00863-3. English, Spanish. doi:
10.1016/j.ad.2023.10.030. Epub ahead of print. PMID: 37923069.
17: Sánchez-Díaz M, Flórez Á, Ara-Martín M, Arias-Santiago S, Botella-Estrada R,
Cañueto J, Carretero-Hernández G, Coto-Segura P, de Eusebio-Murillo E, García-
Latasa de Araníbar FJ, García-Patos Briones V, Gardeazabal García J, Gómez-
Fernández C, Hernández-Ostiz S, Izu Belloso R, López-Ávila A, Manchado López P,
Martín-Santiago A, Martinez De Espronceda Ezquerro I, Mateu-Puchades A,
Mercader-García P, Notario Rosa J, Palacio Aller L, Pérez-Hortet C, Quintana-
Castanedo L, Rivera R, Rocamora Duran V, Rodríguez-Nevado IM, Ruiz-Villaverde R,
Suárez J, Trasobares-Marugán L, Vizán-de Uña C, Yanguas I, Zulaica-Garate A,
García-Doval I, Descalzo MÁ, Grau-Pérez M, Carrascosa-Carrillo JM. Requirements
for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study.
Actas Dermosifiliogr. 2023 Oct 25:S0001-7310(23)00847-5. English, Spanish. doi:
10.1016/j.ad.2023.10.016. Epub ahead of print. PMID: 37890617.
18. Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la
Cueva P, Belinchón I. A New Classification of the Severity of Psoriasis: What's
Moderate Psoriasis? Life (Basel). 2021 Jun 29;11(7):627. doi:
10.3390/life11070627. PMID: 34209585; PMCID: PMC8307918.
19: Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Vasquez Chinchay F, Galán-Gutiérrez M. Effectiveness, survival and safety of
guselkumab attending to basal characteristics in moderate-to-severe psoriatic
patients: a cohort study. F1000Res. 2022 Oct 17;11:1178. doi:
10.12688/f1000research.122945.2. PMID: 36567685; PMCID: PMC9755754.
20: Ruiz-Villaverde R, Galán-Gutiérrez M, Llamas-Velasco M, Salgado-Boquete L,
Puig L, de la Cueva P, Carrascosa JM; en representación del Grupo Español de
Psoriasis (GPs). Updated Position of the Spanish Psoriasis Group (GPs) on the
Use of Biosimilar Drugs in Moderate to Severe Psoriasis. Actas Dermosifiliogr.
2023 Jun;114(6):494-501. English, Spanish. doi: 10.1016/j.ad.2023.02.016. Epub
2023 Mar 10. PMID: 36906260.
21: Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Galán-Gutiérrez M. Super responders to guselkumab treatment in moderate-to-
severe psoriasis: a real clinical practice pilot series. Int J Dermatol. 2022
Aug;61(8):1029-1033. doi: 10.1111/ijd.15784. Epub 2021 Nov 3. PMID: 34731493.
22: Ruiz-Villaverde R, Galan-Gutierrez M, Armario-Hita JC, Rodriguez-Fernandez-
Freire L. Efficacy and pharmacoeconomic analysis in real clinical practice
conditions of patients with plaque psoriasis treated with guselkumab: A
retrospective multicenter study. Actas Dermosifiliogr. 2023 Nov
1:S0001-7310(23)00855-4. English, Spanish. doi: 10.1016/j.ad.2023.10.023. Epub
ahead of print. PMID: 37923077.
23: Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil
A, Chinchay FV, Galán-Gutiérrez M. Guselkumab as a switching strategy after
anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
Dermatol Ther. 2022 Oct;35(10):e15760. doi: 10.1111/dth.15760. Epub 2022 Aug 15.
PMID: 35971573.
24: Ruiz-Villaverde R, Chinchay FV, Rodriguez-Fernandez-Freire L, Armario-Hita
JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab dosing interval optimization in
adult patients with moderate-to-severe psoriasis switching from ustekinumab.
Dermatol Ther. 2022 Nov;35(11):e15835. doi: 10.1111/dth.15835. Epub 2022 Sep 23.
PMID: 36114755.
25: Herranz P, Trasobares L, Mateu A, Martínez E, Ruiz-Villaverde R, Baniandrés
O, Mataix Díaz J, Jiménez-Gómez N, Serra M, Ruiz Genao DP, Rivera N, Tercedor-
Sánchez J, Garcia C, Cordey M, Herrera-Acosta E. Characterization and Outcomes
in Patients Treated With Apremilast in Routine Clinical Practice in Spain:
Results From the APPRECIATE Study. Actas Dermosifiliogr (Engl Ed). 2021 May
27:S0001-7310(21)00202-7. English, Spanish. doi: 10.1016/j.ad.2021.05.010. Epub
ahead of print. PMID: 34052202.
26: Galán-Gutierrez M, Rodriguez-Fernandez Freire L, Ruiz-Villaverde R.
Tildrakizumab: short-term efficacy and safety in real clinical practice. Int J
Dermatol. 2022 Sep;61(9):e355-e357. doi: 10.1111/ijd.15840. Epub 2021 Oct 11.
PMID: 34632570.
27: Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Pérez-Gil A, Font-Ugalde P,
Galán-Gutiérrez M. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term
(52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the
Therapeutic Goals of the Spanish Psoriatic Guidelines. Life (Basel). 2022 Nov
14;12(11):1883. doi: 10.3390/life12111883. PMID: 36431015; PMCID: PMC9697008.
28: Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-
Gutierrez M. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks)
in Three Tertiary Hospitals in Andalucia (Spain). J Clin Med. 2022 Aug
30;11(17):5098. doi: 10.3390/jcm11175098. PMID: 36079026; PMCID: PMC9456674.
29: Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC.
Switching from reference adalimumab to biosimilar. Assessment of clinical
outcomes in psoriasis. Int J Dermatol. 2023 Mar;62(3):e159-e161. doi:
10.1111/ijd.16399. Epub 2022 Aug 10. PMID: 35948826.
30. Ruiz-Villaverde R, Ruiz-Carrascosa JC, Galán-Gutierrez M, Armario-Hita JC.
Risankizumab: A pilot study of short-term effectiveness and safety in real
clinical practice. Dermatol Ther. 2021 Jan;34(1):e14711. doi: 10.1111/dth.14711.
Epub 2021 Jan 6. PMID: 33368889.
31: Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, Julià M, Ruiz-Villaverde
R, Rodríguez Fernández-Freire L, Notario J, Llamas-Velasco M, Ferran M,
Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque
psoriasis at 52 weeks in a real-world clinical setting: observational,
retrospective, multi-centre study by the Spanish Psoriasis Group. J Dermatolog
Treat. 2022 Sep;33(6):2878-2880. doi: 10.1080/09546634.2022.2079596. Epub 2022
May 26. PMID: 35593480.
32: Vidal S, Puig L, Carrascosa-Carrillo JM, González-Cantero Á, Ruiz-Carrascosa
JC, Velasco-Pastor AM. From Messengers to Receptors in Psoriasis: The Role of
IL-17RA in Disease and Treatment. Int J Mol Sci. 2021 Jun 23;22(13):6740. doi:
10.3390/ijms22136740. Erratum in: Int J Mol Sci. 2022 Feb 28;23(5): PMID:
34201664; PMCID: PMC8268646.
33: Mataix J, García L, Belinchón I, Ruiz Carrascosa JC, de la Cueva P,
Carrascosa JM. Moderate to Severe Psoriasis in Older Adults: Recommendations on
Management from the Psoriasis Working Group of the Spanish Academy of
Dermatology and Venereology (AEDV). Actas Dermosifiliogr. 2023
Oct;114(9):802-811. English, Spanish. doi: 10.1016/j.ad.2023.05.016. Epub 2023
May 25. PMID: 37244396.
34: Dodero-Anillo JM, Lozano-Cuadra IC, Rios-Sanchez E, Pedrosa-Martinez MJ,
Ruiz-Carrascosa JC, Galan-Gutierrez M, Armario-Hita JC. Optimising the
Therapeutic Interval for Biologics in Patients with Psoriasis. Life (Basel).
2022 Dec 10;12(12):2075. doi: 10.3390/life12122075. PMID: 36556440; PMCID:
PMC9787329.
35: Gratacós J, Luelmo J, Rodríguez J, Notario J, Marco TN, de la Cueva P,
Busquets MP, Font MG, Joven B, Rivera R, Vega JLA, Álvarez AJC, Parera RS,
Carrascosa JCR, Martínez FJR, Sánchez JP, Olmos CF, Pujol C, Galindez E, Barrio
SP, Arana AU, Hergueta M, Coto P, Queiro R. Standards of care and quality
indicators for multidisciplinary care models for psoriatic arthritis in Spain.
Rheumatol Int. 2018 Jun;38(6):1115-1124. doi: 10.1007/s00296-018-3986-4. Epub
2018 Feb 7. PMID: 29417210.